ING accelerates growth in Private Banking with strategic investment in leading Spanish wealth manager Singular Bank ING today announced a strategic investment in its Private Banking capabilities by acquiring a stake of approximately 40% in leading Spanish wealth manager Singular Bank. The transaction allows us to accelerate our growth in Private Banking and Wealth Management in the attractive Spanish market. This fits into our ‘Growing the difference’ strategy to increase impact in the markets we operate in, expanding in product offerings and business segments and becoming more relevant for specific client groups. Singular Bank is a leading independent Spanish private bank with around €19 billion of client’s invested assets, offering a complete range of products and services to high-net-worth individuals. ING acquires the stake from...

Adds potential first-in-class, N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform, designed to address resistance to current payloadsStrengthens the Novartis oncology pipeline with two lead ADC assets and a broader payload platform with potential impact across multiple solid tumor settingsBasel, July 6, 2026 – Novartis today announced that it has entered into an agreement to acquire Myricx Bio (“Myricx”), a privately held UK-based biotechnology company developing a new class of antibody-drug conjugates (ADCs), using N-myristoyltransferase inhibitor (NMTi) payloads. The proposed acquisition would strengthen the Novartis oncology pipeline and advance next-generation targeted drug conjugates with novel payload mechanisms. Myricx’s approach is designed to deliver a differentiated cancer-killing...

MELBOURNE, Australia, July 06, 2026 (GLOBE NEWSWIRE) — Brandon Capital, Australasia’s leading life sciences venture capital firm, today announces the successful exit of its portfolio company Myricx Bio following its agreement to be acquired by Novartis. The transaction is valued at up to US$1.5 billion (~A$2.16bn) including an upfront cash payment of US$1.1 billion (~A$1.58bn) plus potential milestone payments. Myricx Bio is a UK-based pre-clinical oncology company developing a novel class of payloads for antibody-drug conjugates (ADCs). One of the most important emerging modalities in cancer therapy, ADCs combine the targeting precision of antibodies with the tumour-killing activity of potent small-molecule payloads. The acquisition advances ADC innovation by bringing together the strengths of Novartis in oncology with Myricx’s...

Potential first-in-class N-myristoyltransferase inhibitor (NMTi) ADC payload with a differentiated mechanism of action Combines oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad potential across multiple solid tumour types Transaction valued at up to $1.5 billion including $1.1 billion cash upfrontLONDON, July 06, 2026 (GLOBE NEWSWIRE) — Myricx Bio, a UK-headquartered biotech company focusing on the discovery and development of a novel class of payloads for antibody-drug conjugates (ADCs), today announced that it has reached agreement to be acquired by Novartis for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. The acquisition advances ADC innovation by bringing together the strengths of Novartis in oncology with Myricx Bio’s two lead ADC assets...

VANCOUVER, British Columbia, July 03, 2026 (GLOBE NEWSWIRE) — Canfor Corporation (TSX: CFP) is pleased to announce it has completed the acquisition of PinkWood Ltd, Western Canada’s largest I-joist facility based in Calgary, Alberta. The acquisition, announced on June 9, 2026, complements Canfor’s existing operations in Alberta and British Columbia. “We’re excited to welcome the PinkWood operation, its management team and its employees to the Canfor family,” said Susan Yurkovich, President and CEO of Canfor. “The acquisition represents a strong strategic fit for both companies and supports the continued growth of Canfor’s value-added manufacturing capabilities.” PinkWood will retain its name and operate as a wholly owned subsidiary of Canfor. The operation will add 120 employees, and 46 million linear feet of annual I-joist production...

Nexans completes the sale of Autoelectric to Motherson  Paris, July 3rd, 2026 – Nexans announces today the completion of the sale of its wiring harness business, Autoelectric, to Samvardhana Motherson International Limited (“Motherson”), a leading global supplier of automotive systems and components, for an Enterprise Value of €207 million. In 2025 and up until its deconsolidation from Nexans as of July 1st 2026, the wiring harness business along with the Industry and Solutions segment was classified as discontinued operations in the consolidated financial statements of the Group. Its contribution remains fully excluded from the 2026 guidance. Autoelectric standalone generated current annual sales of c. €708 million in 2025 with nearly 13,000 employees. This divestment completes the portfolio rotation Nexans announced in 2021, with Autoelectric...

Amendments to implementation mechanics do not change the agreed Scheme consideration, the principal conditions to completion, or the strategic rationale for the transaction NEW YORK, July 03, 2026 (GLOBE NEWSWIRE) — Critical Metals Corp. (Nasdaq: CRML) (“Critical Metals Corp” or the “Company”), a leading critical minerals mining company, announced that it and European Lithium Limited (ASX: EUR, FRA: PF8, OTC: EULIF) (“European Lithium”) have entered into an amendment deed to the Scheme Implementation Deed governing Critical Metals’ proposed acquisition of European Lithium. The amendments reflect agreed changes to certain implementation mechanics of the transaction while preserving the existing commercial terms of the proposed acquisition. The principal amendments include:European Lithium shareholders and listed...

  RENK Group AG bolsters leading position in the naval sector with acquisition of David Brown Defence from Stellex Capital ManagementDavid Brown Defence is a leading UK based supplier for high-performing transmission solutions to long-term UK and international defense programs Strong UK home market with access to UK and allied nations naval and land defense programs including Global Combat Ship (GCS) Significant synergy potential through the combination of technological and operational know-how as well as optimal capacity utilization and joined go-to-market Unique expertise in submarine gearboxes with low noise and vibration levels: technological basis for the next generation of submarine platforms Expanding RENK’s land defense portfolio to include UK programs such as Challenger 2 and Boxer Secured order backlog and strong pipeline...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ANIMALCARE GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ADVANCED MEDICAL SOLUTIONS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...